Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 25:385:e078242.
doi: 10.1136/bmj-2023-078242.

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study

Nikita Simms-Williams  1 , Nir Treves  2 , Hui Yin  1 , Sally Lu  3 , Oriana Yu  3   4 , Richeek Pradhan  5 , Christel Renoux  3   6   7 , Samy Suissa  3   6 , Laurent Azoulay  8   6   9
Affiliations

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study

Nikita Simms-Williams et al. BMJ. .

Erratum in

Abstract

Objective: To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious renal events compared with either drug class alone among patients with type 2 diabetes, and to assess the effect of the combination on the individual components of major adverse cardiovascular events, heart failure, and all cause mortality.

Design: Population based cohort study using a prevalent new-user design, emulating a trial.

Setting: UK Clinical Practice Research Datalink linked to Hospital Episode Statistics Admitted Patient Care and Office for National Statistics databases.

Participants: Two prevalent new-user cohorts were assembled between January 2013 and December 2020, with follow-up until the end of March 2021. The first cohort included 6696 patients who started GLP-1 receptor agonists and added on SGLT-2 inhibitors, and the second included 8942 patients who started SGLT-2 inhibitors and added on GLP-1 receptor agonists. Combination users were matched, in a 1:1 ratio, to patients prescribed the same background drug, duration of background drug, and time conditional propensity score.

Main outcome measures: Cox proportional hazards models were fitted to estimate the hazard ratios and 95% confidence intervals of major adverse cardiovascular events and serious renal events, separately, comparing the GLP-1 receptor agonist-SGLT-2 inhibitor combination with the background drug, either GLP-1 receptor agonists or SGLT-2 inhibitors, depending on the cohort. Secondary outcomes included associations with the individual components of major adverse cardiovascular events (myocardial infarction, ischaemic stroke, cardiovascular mortality), heart failure, and all cause mortality.

Results: Compared with GLP-1 receptor agonists, the SGLT-2 inhibitor-GLP-1 receptor agonist combination was associated with a 30% lower risk of major adverse cardiovascular events (7.0 v 10.3 events per 1000 person years; hazard ratio 0.70, 95% confidence interval 0.49 to 0.99) and a 57% lower risk of serious renal events (2.0 v 4.6 events per 1000 person years; hazard ratio 0.43, 0.23 to 0.80). Compared with SGLT-2 inhibitors, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a 29% lower risk of major adverse cardiovascular events (7.6 v 10.7 events per 1000 person years; hazard ratio 0.71, 0.52 to 0.98), whereas serious renal events generated a wide confidence interval (1.4 v 2.0 events per 1000 person years; hazard ratio 0.67, 0.32 to 1.41). Secondary outcomes generated similar results but with wider confidence intervals.

Conclusions: In this cohort study, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a lower risk of major adverse cardiovascular events and serious renal events compared with either drug class alone.

PubMed Disclaimer

Conflict of interest statement

Competing interests All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: this study was funded by the Canadian Institutes of Health Research; LA received speaking and consulting fees from Pfizer and Roche for work unrelated to this project; SS attended scientific advisory committee meetings for AstraZeneca, Atara, Bristol-Myers-Squibb, Merck, Novartis, Panalgo, Pfizer, and Seqirus and received speaking fees from Boehringer-Ingelheim and Novartis; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Study flowchart for construction of glucagon-like peptide-1 (GLP-1) receptor agonist (RA)-sodium-glucose cotransporter-2 (SGLT-2) inhibitor combination users versus GLP-1 RA users cohort. An individual can represent multiple matching opportunities at different times during follow-up period; thus, number of possible matches exceeds total number of patients. ESRD=end stage renal disease
Fig 2
Fig 2
Cumulative incidence curves of major adverse cardiovascular events (MACE) for glucagon-like peptide-1 (GLP-1) receptor agonist (RA)-sodium-glucose cotransporter-2 (SGLT-2) inhibitor combination versus GLP-1 RAs
Fig 3
Fig 3
Study flowchart for construction of glucagon-like peptide-1(GLP-1) receptor agonist (RA)-sodium-glucose cotransporter-2 (SGLT-2) inhibitor combination users versus SGLT-2 inhibitor users cohort. An individual can represent multiple matching opportunities at different times during follow-up period; thus, number of possible matches exceeds total number of patients. ESRD=end stage renal disease
Fig 4
Fig 4
Cumulative incidence curves of major adverse cardiovascular events (MACE) for glucagon-like peptide-1(GLP-1) receptor agonist (RA)-sodium-glucose cotransporter-2 (SGLT-2) inhibitor combination versus SGLT-2 inhibitors
See this image and copyright information in PMC

References

    1. American Diabetes Association . 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021 . Diabetes Care 2021;44(Suppl 1):S111-24. 10.2337/dc21-S009 - DOI - PubMed
    1. Lipscombe L, Butalia S, Dasgupta K, et al. Diabetes Canada Clinical Practice Guidelines Expert Committee . Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Can J Diabetes 2020;44:575-91. 10.1016/j.jcjd.2020.08.001 - DOI - PubMed
    1. Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-30. 10.1016/S0140-6736(19)31149-3 - DOI - PubMed
    1. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee. LEADER Trial Investigators . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311-22. 10.1056/NEJMoa1603827 - DOI - PMC - PubMed
    1. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-44. 10.1056/NEJMoa1607141 - DOI - PubMed

Publication types

MeSH terms

Substances